Radiation oncology vendor Elekta has formed a new partnership with IBM Watson Health to offer the Watson for Oncology artificial intelligence (AI) platform along with its offerings for cancer care.
Developed by IBM in collaboration with Memorial Sloan Kettering Cancer Center in New York City, Watson for Oncology is designed to summarize a patient's key medical attributes and provide information to oncologists to help them deliver treatment options based on training from the Memorial Sloan Kettering oncologists, according to Elekta.
The software also ranks treatment options, linking to peer-reviewed studies that have been curated by Memorial Sloan Kettering. In addition, Watson for Oncology provides a large corpus of medical literature -- more than 300 medical journals, over 200 textbooks, and nearly 15 million of pages of text -- to offer insight into different treatment options, Elekta said.
Beginning in early 2018, Elekta will sell Watson for Oncology as a clinical decision-support application paired within its cancer-care software, including the Mosaiq oncology information system. Elekta plans to offer both products in most markets around the world, including the U.S., Brazil, and certain major European and Asian markets, as well as India and Australia.
